COVID-19 Post-Vaccination Observation
NCT06107348 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2023-10-30
Summary
The study started after the second COVID-19 vaccination of the participant with blood spots appearing on the skin with severe arthritis. The study continued to the third-dose full vaccination of the participant with the recombined COVID-19 vaccination and afterwards. The study completed until intervention.
Conditions
- Immune System Diseases
- COVID-19 Vaccine Adverse Reaction
- Immune System Disorder
Sponsors & Collaborators
-
Yang I. Pachankis, PhD
lead INDIV
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-07-01
- Primary Completion
- 2023-01-04
- Completion
- 2023-12-24
Countries
- China
Study Locations
More Related Trials
-
Vaccination Against SARS-Cov2 (COVID-19) in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.
NCT04970550 ·Status: COMPLETED
-
SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism
NCT04584541 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
NCT00282308 ·Status: COMPLETED ·Phase: PHASE2
-
The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
NCT05543642 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs
NCT04530682 ·Status: COMPLETED
-
A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate
NCT02147587 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
NCT04315298 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
NCT03486457 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis
NCT07008846 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
COVID-19 VaccinE Response in Rheumatology Patients
NCT05080218 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
NCT04885829 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
NCT00279734 ·Status: COMPLETED ·Phase: PHASE1
-
MTX Hold During Covid-19 Booster
NCT05313061 ·Status: UNKNOWN ·Phase: PHASE3
-
Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients
NCT04880720 ·Status: COMPLETED
-
COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases
NCT04335747 ·Status: TERMINATED
-
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
NCT02955212 ·Status: COMPLETED ·Phase: PHASE3
-
Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases
NCT05026892 ·Status: UNKNOWN
-
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
NCT06087406 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19
NCT05056558 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
NCT06857227 ·Status: RECRUITING ·Phase: PHASE1
-
Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines
NCT00993668 ·Status: COMPLETED ·Phase: PHASE4
-
A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo
NCT01359150 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)
NCT01651936 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
NCT07087912 ·Status: RECRUITING ·Phase: PHASE4
-
Duration of Immune Response to Influenza Vaccination in Patients With RA
NCT02311855 ·Status: COMPLETED ·Phase: PHASE4